Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844512 | 0.86 | ALDH1A1 (0.34) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL29300080 | 0.85 | ALDH1A1 (0.39) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL9653822 | 0.80 | MAPT (0.35) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL648441 | 0.79 | MAPT (0.39) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL11897282 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL11897934 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL11897790 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL9652302 | 0.76 | TSHR (0.41) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL11995948 | 0.74 | SMN1; SMN2 (0.38) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT | |
| SCHEMBL31726014 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TP53SMN1; SMN2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1550664-B1 | SILICON COMPOUND | JNC CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1650214-B1 | Silicon compound | CHISSO CORP (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-1686133-B1 | Organosilicon compound | CHISSO CORP (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-7399819-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7375170-B2 | Organosilicon compound | CHISSO CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1849787-A1 | Organosilicon compound | Chisso Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849788-A1 | Organosilicon compound | Chisso Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-7256243-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7235619-B2 | Silsesquioxane derivative | CHISSO CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| US-20060175684-A1 | Organosilicon compound | JNC PETROCHEMICAL CORPORATION (JP) | 2006-08-10 | — | — | US | disclosed |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | ITO KENYA | 2006-04-27 | — | — | US | disclosed |
| EP-1650214-A2 | Silicon compound | CHISSO CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550664-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1546225-A1 | ELASTOMERIC, EXPANDABLE HYDROGEL COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| WO-2004026928-A1 | ELASTOMERIC, EXPANDABLE HYDROGEL COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040054026-A1 | Elastomeric, expandable hydrogel compositions | BAUSCH & LOMB INCORPORATED | 2004-03-18 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | ALDH1A1 535/4885TP53 3637/4885SMN1; SMN2 2308/4885 |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | SFXN1, STS, SRM | ALDH1A1 597/4885TP53 4301/4885SMN1; SMN2 2580/4885 |
| US-20040054026-A1 | Elastomeric, expandable hydrogel compositions | UACA, CRYAA, LAGE3 | ALDH1A1 2579/4885TP53 2038/4885SMN1; SMN2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.